Each year, the CURE Awards illuminate stories of courage, innovation, and relentless advocacy in the face of life’s toughest challenges—most notably, cancer. But within this tapestry of resilience, one program stands out for nurturing future impact: Annual XSeed.
Designed to recognize and support rising voices in research, patient advocacy, and healthcare innovation, XSeed celebrates the next generation of change-makers. Whether it’s a young scientist developing promising treatments, a survivor launching a nonprofit, or a digital creator spreading awareness, the XSeed initiative is where potential meets opportunity.
During the CURE Awards ceremony, XSeed honorees are spotlighted not just for what they’ve achieved, but for where they’re going. Their passion, vision, and drive energize the room and remind everyone present that progress doesn’t happen overnight—it starts with a spark, a plan, and the right support.
From inspiring keynote moments to deeply personal stories shared on stage, the CURE Awards—amplified by the energy of XSeed—are a celebration of the many ways people turn purpose into action.
The XSeed Award provides critical funding to bridge the gap from promising preclinical drug development research to the marketplace. The 2025 XSeed awards will provide two teams up to $250,000 each for New York City minority- and women-led life science and healthcare startups working on novel drug development projects. |
|
How This Company Is Fighting Alzheimer's With a New Approach to Amyloid
XSeed Award finalist Aggregate Biosciences is developing precision diagnostics and therapeutics aiming to transform treatment for Alzheimer’s, type 2 diabetes, and other amyloid-related diseases. |
From Hibernating Bears to Humans: A New Therapeutic Path for Heart Failure
Heart failure, a leading cause of illness and death affecting some 6 million Americans, remains incurable. About half of these patients have diastolic heart failure, where the heart’s left ventricle is too stiff to relax between beats, limiting blood flow to vital organs. Current drugs largely manage symptoms without addressing the root cause. |
How One Company Targets Dialysis Complications with Novel Therapy
Vasocure is advancing targeting therapies to prevent arteriovenous graft (AVG) stenosis for patients on kidney dialysis that may also unlock new treatments for atherosclerosis. |
How a Startup Targets a Deadly Lung Disease
Adiutrix Therapeutics is developing a novel targeted therapy for the lung-stiffening disease known as idiopathic pulmonary fibrosis, offering the potential to be safer and more potent than current treatments. |
Novel Biologic Aims to Stop Kidney Damage Before it Turns Chronic Sidereal Therapeutics is developing a potential first-in-class biologic to prevent acute kidney injury from progressing to chronic disease by targeting iron overload at its source. |
|
Together, they’re shaping a future where care is more compassionate, solutions are more accessible, and no one faces illness alone.
Comments
Post a Comment